AstraZeneca’s (AZN) Buy Rating Reaffirmed at Jefferies Financial Group

AstraZeneca (LON:AZN – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Jefferies Financial Group in a report issued on Friday,Digital Look reports. They currently have a £180 target price on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price would suggest a potential upside of 26.12% from the company’s current price.

Other research analysts have also issued reports about the stock. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 price objective on shares of AstraZeneca in a research note on Thursday, June 11th. Citigroup raised their price target on AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a report on Friday, April 10th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of £153.33.

Get AstraZeneca alerts:

Check Out Our Latest Analysis on AZN

AstraZeneca Stock Performance

AZN stock traded up GBX 210 on Friday, hitting £142.72. The company’s stock had a trading volume of 50,969,355 shares, compared to its average volume of 35,587,070. The stock has a market cap of £221.34 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21. The firm has a 50 day moving average of £138.04 and a two-hundred day moving average of £141.13. The company has a current ratio of 0.91, a quick ratio of 0.59 and a debt-to-equity ratio of 71.66. AstraZeneca has a 1 year low of £101.03 and a 1 year high of £157.32.

AstraZeneca Company Profile

(Get Free Report)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Featured Articles

• Five stocks we like better than AstraZeneca
• Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
• Xcel Energy Stock Offers Stability as Electricity Demand Builds
• Data Center Delays Create Opportunity in These 3 Stocks
• Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally Here

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.